of an annual $90 billion market opportunity. InSitu Biologics' focus ... of shares is nearly sold out. InSitu Biologics is accepting a limited amount of investments at $6.90 per share. *Due to the demand for InSitu Biologics’ stock, ...
GATC Health is transforming how we diagnose and treat disease.
and Biology, the official journal of WMIS. Dr. Moore holds a PhD in Bioorganic ... biology, genetics, and tumor biology and therapy. She developed the core ... (small-molecule/biologics/nucleic acid-based) and Biomarker Development; (Companion) Diagnostics (IVD, ...
in InSitu Biologics' AnestaGel™, a patented non-opioid pain relief drug ... will then receive a private invitation to invest from InSitu Biologics ...
sclerosis (MS), or who have suffered a stroke or have nerve injuries. ...
know, this is clearly optimism, and I see the comments coming in to our ... a Regulation A+ for a company insights to biologics and non-opioid pain killing, ...
and improvements Check out Golf Suites 1 InSitu Biologics - Anyone can invest ...
unit price. Insitu Biologics Completed Their Raise to fund AnestaGel™, ...
in InSitu Biologics' AnestaGel™, a non-opioid pain relief drug based ...
investment $500. InSitu Biologics - Max raise $10mill. Anyone can invest ...
